Candidoses invasives en réanimation : données épidémiologiques, élaboration d’un score prédictif et mise au point de PCR pour le diagnostic

Patients in intensive care units (ICU) are at very high risk of invasive candidiasis associated with high mortality rate. Candida species are the third cause of septicemia. Clinical signs lack of specificity and blood cultures lack of sensitivity, and therefore the diagnosis remains a challenge. In order to improve the identification of patients with invasive candidiasis, predictive rules, biomarkers and PCR have been developed. The first part of this work describes the evolution over a ten years period in one ICU in Candida species distribution, susceptibility to antifungal drugs and consumption of antifungal agents. Changes in antifungal drug consumption were observed but they were not associated with significant changes in fungal ecology or with the emergence of resistant species. In a second part, we present a prospective, observational and bicentric study performed in 435 non-neutropenic patients in ICU. Several variables (risk factors of invasive candidiasis, Candida colonization, mannan antigen and anti-mannan antibodies) were analyzed and a predictive score of invasive candidiasis has been developed. Finally, the last part presents the development of Candida real-time PCR in blood, as well as the evaluation of a digital PCR.Les patients de réanimation sont des patients à très haut risque de survenue de candidoses invasives associées à une importante mortalité. Les espèces du genre Candida sont retrouvées en troisième position des agents infectieux les plus fréquemment isolés au cours des septicémies. Le diagnostic reste difficile en raison d’une clinique aspécifique et d’une sensibilité médiocre des hémocultures. Des scores prédictifs, des biomarqueurs ou encore des PCR ont été développés de manière à améliorer le diagnostic et l’identification des patients à risque. Dans ce travail, la première partie présente les données de l’évolution de l’écologie fongique, des candidoses invasives, des prescriptions d’antifongiques et des sensibilités aux antifongiques sur une période de dix ans dans un service de réanimation. Au cours de cette période, les changements observés dans la prescription d’antifongiques n’ont pas entrainé de modifications significatives de l’écologie fongique ni d’apparition de résistances. Dans une deuxième partie, nous présentons les résultats d’une étude prospective observationnelle bicentrique réalisée chez 435 patients non neutropéniques de réanimation. L’analyse de plusieurs variables (facteurs de risque de candidose invasive, colonisation à Candida sp., dosages d’antigène mannane et d’anticorps anti-mannane) a permis l’élaboration d’un score prédictif de survenue de candidose invasive. Finalement, la dernière partie du travail présente la mise au point de PCR Candida en temps réel dans le sang ainsi qu’une évaluation de la technologie de digital PCR

Invasive candidiasis in intensive care unit : epidemiology, development of a predictive score and PCR for the diagnosis

Les patients de réanimation sont des patients à très haut risque de survenue de candidoses invasives associées à une importante mortalité. Les espèces du genre Candida sont retrouvées en troisième position des agents infectieux les plus fréquemment isolés au cours des septicémies. Le diagnostic reste difficile en raison d’une clinique aspécifique et d’une sensibilité médiocre des hémocultures. Des scores prédictifs, des biomarqueurs ou encore des PCR ont été développés de manière à améliorer le diagnostic et l’identification des patients à risque. Dans ce travail, la première partie présente les données de l’évolution de l’écologie fongique, des candidoses invasives, des prescriptions d’antifongiques et des sensibilités aux antifongiques sur une période de dix ans dans un service de réanimation. Au cours de cette période, les changements observés dans la prescription d’antifongiques n’ont pas entrainé de modifications significatives de l’écologie fongique ni d’apparition de résistances. Dans une deuxième partie, nous présentons les résultats d’une étude prospective observationnelle bicentrique réalisée chez 435 patients non neutropéniques de réanimation. L’analyse de plusieurs variables (facteurs de risque de candidose invasive, colonisation à Candida sp., dosages d’antigène mannane et d’anticorps anti-mannane) a permis l’élaboration d’un score prédictif de survenue de candidose invasive. Finalement, la dernière partie du travail présente la mise au point de PCR Candida en temps réel dans le sang ainsi qu’une évaluation de la technologie de digital PCR.Patients in intensive care units (ICU) are at very high risk of invasive candidiasis associated with high mortality rate. Candida species are the third cause of septicemia. Clinical signs lack of specificity and blood cultures lack of sensitivity, and therefore the diagnosis remains a challenge. In order to improve the identification of patients with invasive candidiasis, predictive rules, biomarkers and PCR have been developed. The first part of this work describes the evolution over a ten years period in one ICU in Candida species distribution, susceptibility to antifungal drugs and consumption of antifungal agents. Changes in antifungal drug consumption were observed but they were not associated with significant changes in fungal ecology or with the emergence of resistant species. In a second part, we present a prospective, observational and bicentric study performed in 435 non-neutropenic patients in ICU. Several variables (risk factors of invasive candidiasis, Candida colonization, mannan antigen and anti-mannan antibodies) were analyzed and a predictive score of invasive candidiasis has been developed. Finally, the last part presents the development of Candida real-time PCR in blood, as well as the evaluation of a digital PCR

Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study

International audienceMonitoring fungal ecology and resistance to antifungal agents within intensive care units (ICU) is essential for the management of invasive fungal infections. Therefore, a retrospective descriptive study was carried in the ICU of Nimes University Hospital, France, from 2007 to 2016. As the majority of invasive fungal infections in ICU are caused by Candida species, the study objectives were to describe Candida species distribution, to assess candidaemia incidence and to monitor the antifungal drug susceptibility of Candida isolates and the consumption of antifungal agents. Among the recorded invasive Candida infections (n=244), 43% were intra-abdominal and 22% bloodstream infections. Candida albicans was the most frequent species (55.8%), followed by Candida glabrata (14.1%), Candida tropicalis (10%), Candida parapsilosis (8%) and Candida krusei (5.3%). Candidaemia incidence was 4.49 per 1000 admissions. The mean consumption of antifungal agents was of 170.5 defined daily doses (DDD) for 1000 hospital days (HD) per year. Changes in antifungal drug consumption were observed, with an increased use of echinocandins (from 17.96 DDD/1000 HD in 2007 to 48.76 DDD/1000 HD in 2016), and the total treatment cost tripled during the study period. No significant change in fungal ecology or in the emergence of resistant species was observed; indeed, only 1.1% of isolates presented an unusual resistance to antifungal agents

Kazachstania slooffiae: An unexpected journey to a human pleural sample

International audienceWe report a case of a 50-year-old shepherd hospitalized in intensive care unit for hiatal hernia complicated by an occlusive syndrome. In post-surgery, an acute respiratory distress occurs due to mediastinitis with large pleural effusion. At the laboratory, direct examination of the pleural sample revealed the presence of pseudohyphae. Kazachstania slooffiae was identified by Mass Spectrometry and confirmed by DNA sequencing. This uncommon yeast has never been previously described in human infections. Although its pathogenicity is not well known, K. slooffiae should be considered in the case of critically ill patients

Kazachstania slooffiae: An unexpected journey to a human pleural sample

International audienceWe report a case of a 50-year-old shepherd hospitalized in intensive care unit for hiatal hernia complicated by an occlusive syndrome. In post-surgery, an acute respiratory distress occurs due to mediastinitis with large pleural effusion. At the laboratory, direct examination of the pleural sample revealed the presence of pseudohyphae. Kazachstania slooffiae was identified by Mass Spectrometry and confirmed by DNA sequencing. This uncommon yeast has never been previously described in human infections. Although its pathogenicity is not well known, K. slooffiae should be considered in the case of critically ill patients

Limitation of Screening of Different Variants of SARS-CoV-2 by RT-PCR

International audienceSince January 2021, the diffusion of the most propagated SARS-CoV-2 variants in France (UK variant 20I/501Y.V1 (lineage B.1.1.7), 20H/H501Y.V2 (lineage B.1.351) and 20J/H501Y.V3 (lineage P.1)) were urgently screened, needing a surveillance with an RT-PCR screening assay. In this study, we evaluated one RT-PCR kit for this screening (ID SARS-CoV-2/UK/SA Variant Triplex®, ID Solutions, Grabels, France) on 2207 nasopharyngeal samples that were positive for SARS-CoV-2. Using ID Solutions kit, 4.1% (92/2207) of samples were suspected to belonged to B.1.351 or P.1 variants. Next-generation sequencing that was performed on 67.4% (62/92) of these samples confirmed the presence of a B.1.351 variant in only 75.8% of the samples (47/62). Thirteen samples belonged to the UK variant (B.1.1.7), and two to A.27 with N501Y mutation. The thirteen with the UK variant presented one mutation in the S-gene, near the ΔH69/ΔV70 deletion (S71F or A67S), which impacted the detection of ΔH69/ΔV70 deletion. Using another screening kit (PKampVariantDetect SARS-CoV-2 RT-PCR combination 1 and 3® PerkinElmer, Waltham, MA, USA) on the misidentified samples, we observed that the two mutations, S71F or A67S, did not impact the detection of the UK variant. In conclusion, this study highlights the limitations of the screening strategy based on the detection of few mutations/deletions as well as it not being able to follow the virus evolution

Diagnosis of Congenital Toxoplasmosis: Performance of Four IgG and IgM Automated Assays at Birth in a Tricentric Evaluation

International audienceFor postnatal diagnosis of congenital toxoplasmosis (CT), the gold standard for the detection of anti-Toxoplasma IgM in newborns relies on the immunosorbent agglutination assay (ISAGA), which is manufactured from whole Toxoplasma parasites that become difficult to maintain. For IgG, only the Platelia assay provides a validated assay for cord blood according to the manufacturer, allowing its use in this context. We compared the analytical performance of four commercialized automated assays, Platelia, Abbott, Vidas, and Liaison, for the detection of IgG and IgM in the cord blood or peripheral blood of newborns from women infected during pregnancy. The assays were performed on samples from 509 newborns, collected from the university hospitals of Montpellier, Nîmes, and Toulouse. For IgM, the four assays appeared to be sufficiently informative to be used for congenital toxoplasmosis diagnosis (area under the curve [AUC] > 0.8, receiver operating characteristic [ROC] analysis), with Platelia showing the best performance, similar to ISAGA with regard to accuracy (83%). For the Vidas (76%), Abbott (75%), and Liaison (74%) assays, the accuracy was significantly lower. Maternal treatment significantly decreased the sensitivity of all the assays. For IgG, the four evaluated assays showed a sensitivity of over 90%, with Abbott (95%) and Liaison (94%), exhibiting a significantly higher sensitivity than Platelia (90%). Furthermore, Abbott showed its superiority in the cases of maternal infection during the third trimester. In the context of the newborns of mothers infected by Toxoplasma gondii during pregnancy, to ensure efficient care, Platelia and Abbott seemed to be the most suitable reference tests for the detection of IgM for the former and IgG for the latter

Some undesirable traps which can mislead the pathologist

International audienceIn clinical laboratories, the diagnosis of parasite diseases can sometimes be challenging for non-expert microbiologists. Indeed, in spite of the advent of the molecular biology, macroscopic and microscopic examinations still remain essential. Nonetheless, it is usually not automated and requires great skills to complete the correct diagnosis. It is not infrequent that inert elements mislead to erroneous diagnoses. Through three different concrete examples, this article aims at underscoring the actual risk of parasite misidentification and at highlighting the systematic approach to be conducted in order to enable reliable diagnosis

Rapid diagnostic tests failing to detect infections by Plasmodium falciparum encoding pfhrp2 and pfhrp3 genes in a non-endemic setting

International audienceBackground Rapid diagnostic tests (RDTs) detecting the histidine-rich protein 2 (PfHRP2) have a central position for the management of Plasmodium falciparum infections. Yet, variable detection of certain targeted motifs, low parasitaemia, but also deletion of pfhrp2 gene or its homologue pfhrp3, may result in false-negative RDT leading to misdiagnosis and delayed treatment. This study aimed at investigating the prevalence, and understanding the possible causes, of P. falciparum RDT-negative infections at Montpellier Academic Hospital, France. Methods The prevalence of falsely-negative RDT results reported before and after the introduction of a loop-mediated isothermal amplification (LAMP) assay, as part as the malaria screening strategy in January 2017, was analysed. Negative P. falciparum RDT infections were screened for pfhrp2 or pfhrp3 deletion; and exons 2 were sequenced to show a putative genetic diversity impairing PfHRP2 detection. Results The overall prevalence of P. falciparum negative RDTs from January 2006 to December 2018 was low (3/446). Whereas no cases were reported from 2006 to 2016 (0/373), period during which the malaria diagnostic screen was based on microscopy and RDT, prevalence increased up to 4.1% (3/73) between 2017 and 2018, when molecular detection was implemented for primary screening. Neither pfhrp2/3 deletion nor major variation in the frequency of repetitive epitopes could explain these false-negative RDT results. Conclusion This paper demonstrates the presence of pfhrp2 and pfhrp3 genes in three P. falciparum RDT-negative infections and reviews the possible reasons for non-detection of HRP2/3 antigens in a non-endemic setting. It highlights the emergence of falsely negative rapid diagnostic tests in a non-endemic setting and draws attention on the risk of missing malaria cases with low parasitaemia infections using the RDT plus microscopy-based strategy currently recommended by French authorities. The relevance of a novel diagnostic scheme based upon a LAMP assay is discussed

Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018)

The French National Reference Center for Invasive Mycoses and Antifungals leads an active and sustained nationwide surveillance program on probable and proven invasive fungal diseases (IFDs) to determine their epidemiology in France. Between 2012 and 2018, a total of 10,886 IFDs were recorded. The incidence increased slightly over time (2.16 to 2.36/10,000 hospitalization days, P = 0.0562) in relation with an increase of fungemia incidence (1.03 to 1.19/10,000, P = 0.0023), while that of other IFDs remained stable. The proportion of ≥65-year-old patients increased from 38.4% to 45.3% (P < 0.0001). Yeast fungemia (n = 5,444) was due mainly to Candida albicans (55.6%) with stable proportions of species over time. Echinocandins became the main drug prescribed (46.7% to 61.8%), but global mortality rate remained unchanged (36.3% at 1 month). Pneumocystis jirovecii pneumonia (n = 2,106) was diagnosed mostly in HIV-negative patients (80.7%) with a significantly higher mortality than in HIV-positive patients (21.9% versus 5.4% at 1 month, P < 0.0001). Invasive aspergillosis (n = 1,661) and mucormycosis (n = 314) were diagnosed mostly in hematology (>60% of the cases) with a global mortality rate of 42.5% and 59.3%, respectively, at 3 months and significant changes in diagnosis procedure over time. More concurrent infections were also diagnosed over time (from 5.4% to 9.4% for mold IFDs, P = 0.0115). In conclusion, we observed an aging of patients with IFD with a significant increase in incidence only for yeast fungemia, a trend toward more concurrent infections, which raises diagnostic and therapeutic issues. Overall, global survival associated with IFDs has not improved despite updated guidelines and new diagnostic tools